Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778569 | 0.87 | GNAI3 (0.35) | FDPSDNM1OPRM1TSHR | |
| SCHEMBL24424826 | 0.87 | GNAI3 (0.35) | FDPSDNM1OPRM1TSHR | |
| SCHEMBL22990204 | 0.87 | GNAI3 (0.35) | FDPSDNM1OPRM1TSHR | |
| SCHEMBL23733443 | 0.81 | EBP (0.38) | FDPSLMNADNM1EBPSIGMAR1 | |
| SCHEMBL24555502 | 0.81 | EBP (0.38) | FDPSLMNADNM1EBPSIGMAR1 | |
| SCHEMBL23733438 | 0.81 | EBP (0.38) | FDPSLMNADNM1EBPSIGMAR1 | |
| SCHEMBL23733462 | 0.80 | GNAI3 (0.38) | FDPSLMNAMAPT | |
| SCHEMBL22096780 | 0.79 | GNAI3 (0.39) | — | |
| SCHEMBL19780154 | 0.79 | GNAI3 (0.39) | — | |
| SCHEMBL19880406 | 0.79 | GNAI3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | FDPS 1367/4885LMNA 773/4885MAPT 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.